A therapeutic vaccine based on autologous dendritic cells pulsed with CD8+-specific Tax antigens induced sustained immune responses and showed promising effects on three ATLL patients either by stabilizing disease progression or inducing a partial remission [212]. This evidence concerns the gene CD8A and adult T-cell leukemia/lymphoma.